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Background: It is not understood why some pulmonary fibroses such as cryptogenic organizing pneumonia (COP)
respond well to treatment, while others like usual interstitial pneumonia (UIP) do not. Increased understanding of
the structure and function of the matrix in this area is critical to improving our understanding of the biology of
these diseases and developing novel therapies. The objectives herein are to provide new insights into the
underlying collagen- and matrix-related biological mechanisms driving COP versus UIP.
Methods: Two-photon second harmonic generation (SHG) and excitation fluorescence microscopies were used to
interrogate and quantify differences between intrinsic fibrillar collagen and elastin matrix signals in healthy, COP,
and UIP lung.
Results: Collagen microstructure was different in UIP versus healthy lung, but not in COP versus healthy, as indicated by
the ratio of forward-to-backward propagating SHG signal (FSHG/BSHG). This collagen microstructure as assessed by FSHG/
BSHG was also different in areas with preserved alveolar architecture adjacent to UIP fibroblastic foci or honeycomb areas
versus healthy lung. Fibrosis was evidenced by increased col1 and col3 content in COP and UIP versus healthy, with
highest col1:col3 ratio in UIP. Evidence of elastin breakdown (i.e. reduced mature elastin fiber content), and increased
collagen:mature elastin ratios, were seen in COP and UIP versus healthy.
Conclusions: Fibrillar collagen’s subresolution structure (i.e. “microstructure”) is altered in UIP versus COP and healthy
lung, which may provide novel insights into the biological reasons why unlike COP, UIP is resistant to therapies, and
demonstrates the ability of SHG microscopy to potentially distinguish treatable versus intractable pulmonary fibroses.
Keywords: Second harmonic generation, SHG, Fibrosis, Collagen, Matrix, Lung, Pulmonary, Two photon, Fluorescence,
Microscopy, Usual interstitial pneumonia, Idiopathic pulmonary fibrosis, Cryptogenic organizing pneumoniaBackground
Pulmonary fibrosis results from accumulation of fibro-
blasts, scar-forming myofibroblasts, and extracellular
matrix proteins including collagen, often leading to irre-
versible loss of lung function. It can be caused by various
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creativecommons.org/publicdomain/zero/1.0/disorders, and infection. Idiopathic Pulmonary Fibrosis
(IPF) is a severe form of fibrotic lung disease that can pro-
gress to respiratory failure and has a prognosis worse than
lung cancer. There are currently few effective therapies.
Usual interstitial pneumonia (UIP) is the histopathology
underlying IPF and is characterized by heterogeneity of
disease and accumulation of fibroblast foci and collagen
with an emphasis on collagen type I (col1) over type III
(col3) [1, 2], and abnormalities in other matrix molecules
including elastin [3]. IPF is one of many diseases associ-
ated with significant collagen and other matrix proteins article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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interstitial pneumonias, is increasing in prevalence, and it
is a progressive disease that causes significant morbidity
and mortality. The median duration of survival from the
time of diagnosis is only 2.9 years [4, 5]. There are
currently few effective FDA approved treatments for IPF
(for review and overview of current and targeted therapies
for IPF, please see: [6–10]), making research into IPF
pathogenesis critical.
Cryptogenic organizing pneumonia (COP) is another
common fibrotic lung disease. It is also characterized by
accumulation of matrix components resulting in orga-
nized areas of granulation tissue in the lung. Compo-
nents of this pathologic matrix accumulation in COP
also include col1 and col3 (with an emphasis on col3
over col1, in contrast to UIP), fibronectin, and proteo-
glycans [1, 11]. In contrast to UIP, the granulation tissue
found in COP accumulates in the airspaces and small
airways rather than in the interstitial spaces and import-
antly, COP is a treatable disease with most cases respond-
ing to corticosteroids. Although the matrix components of
UIP and COP have some similarities, it is unknown why
the excess matrix in COP can be reabsorbed or cleared
after treatment with corticosteroids while the matrix in UIP
is resistant to treatment and resolution [1].
A growing body of literature supports the roles of matrix
organization and structure as important effectors of fibrotic
lung disease. Extracellular matrix (ECM) components have
important mechanobiological properties including the abil-
ities to activate pro-fibrotic cytokines; regulate cell traffick-
ing; and modulate cell activation, proliferation, survival and
differentiation [12, 13]. The organization and structure of
the ECM, including collagen, also helps regulate availability
of and interactions with a large variety of cell-matrix bind-
ing sites critical for controlling lung function. These find-
ings further reinforce the notion that in biology, structure
is a key determinant of function. Indeed, other data sug-
gests that ECM stiffness regulates key cellular activities that
may contribute to IPF [14], as well as endogenous lung
function [15]. Hence, there is heightened interest in the
content and structure of the matrix, and how abnormal
content and structure may impact lung pathophysiology.
For these reasons, we hypothesized that differences in
ECM structure, and collagen microstructure in particular,
underlie the different natural histories, prognoses, and re-
sponses to treatment of UIP and COP.
To explore this question, we used Second Harmonic
Generation (SHG) Microscopy (SHGM) to compare the
matrix of UIP and COP to that of healthy lung tissue.
SHGM is a variant of two photon (2P) microscopy that can
detect the fibrillar collagens (FCs) without exogenous labels.
The fibril-forming collagens include collagen types 1–3, 5,
11, 24, and 27 [16], and at least several of these FCs such as
types I, III, and V are key players in lung fibroses includingusual interstitial pneumonia (UIP) and cryptogenic organiz-
ing pneumonia (COP) [1–3, 11]. SHGM can be used to in-
terrogate changes in collagen’s macrostructural properties
(e.g. collagen fiber density, arrangement, and organization),
as well as collagen’s subresolution microstructural proper-
ties (e.g. the diameter, order versus disorder, and/or pack-
ing density of collagen fibrils within larger collagen fibers)
[17–22]. These microstructural features of individual col-
lagen fibers, as they can influence SHG directionality from
that fiber (i.e. FSHG/BSHG, defined below), are herein col-
lectively referred to as collagen “microstructure”. In this
aspect, SHGM is unique in its ability to interrogate subre-
solution structure of FCs (e.g. col1 and col3) in intact and
potentially live samples without exogenous labels, abilities
which also make SHGM an attractive potential clinical
and investigational diagnostic tool. Thus this technique
can utilize intrinsic properties of matrix components to
characterize the content and organization of the ECM in
these fibrotic lung diseases.
Using SHGM, herein we describe important differences
in matrix content and organization in UIP/IPF and COP
compared to healthy lung tissue. Specifically, we found
differences in collagen’s subresolution structural properties
in UIP compared to COP and healthy lung as assessed by
SHGM and the FSHG/BSHG ratio. Importantly, even adja-
cent normal UIP tissue exhibited these differences in
collagen microstructure compared to healthy lung, thus
introducing the compelling possibilities that altered colla-
gen microstructure might lead to or correlate with fibrosis
in the relatively intractable disease UIP, but not in the more
treatable COP. We also report different col1:col3 ratios in
UIP versus COP and healthy lung tissue, which is import-
ant especially in the context of our FSHG/BSHG data, be-
cause others have reported that altered col1:col3 ratios can
drive (or perhaps be driven by) changes in FC microstruc-
ture such as fibril diameter [23–25], which is one aspect of
collagen microstructure interrogated by the FSHG/BSHG
ratio [17–22]. Finally, we show both UIP and COP have dif-
ferences in mature elastin fiber content, and elastin:collagen
ratio, suggesting that both fibrotic disease have identifying
physiological differences in matrix structure suggestive of
lung disease, but only the less tractable disease, UIP, ex-
hibits differences in underlying collagen microstructure.
These results are important because they provide new in-
sights into the potential biological and biostructural under-
pinnings of refractory versus “treatable” lung fibroses, with
an emphasis on subresolution collagen microstructure, and
demonstrate SHGM’s potential as a powerful new tool for
aiding in the diagnosis and treatment of lung fibrosis.
Methods
Patient populations and source of tissue
Formalin-fixed paraffin embedded human lung tissue
sections were obtained from the University of Rochester
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protocol, by database search for resected lung tissue
from mixed-sex patients with pathologically confirmed
diagnoses of either UIP or COP. Additional UIP lung tis-
sue was obtained from the NIH sponsored Lung Tissue
Research Consortium. All UIP and COP biopsy speci-
mens contained established, moderate to severe fibrosis
by Pathologist diagnosis. Healthy lung tissue specimens
were obtained from non-smoker subjects who had a
lung biopsy for a lesion that was confirmed either benign
or not primary lung cancer, from regions adjacent to the
lesions that did not contain any portion of the lesion.
Histology and immunohistochemistry
Immunohistochemistry (IHC) for col1 and col3 was per-
formed as previously described [19] and excerpted in part
herein (with modifications). Briefly, formalin fixed paraffin
embedded (FFPE) lung biopsies obtained as above were
sectioned at 15 um, then static-mounted on positively
charged slides. For IHC, sections were deparaffinized with
xylene and graded ethanols, followed by 30 minutes micro-
waving (65 °C) in sodium citrate solution for antigen re-
trieval, 2 × 5 min in sterile PBS, then blocked for one hour
(10 % goat serum, 0.5 % BSA, 0.2 % Triton-X, 0.3 M glycine
in PBS). Primary antibodies for Collagen I (#C2456, Sigma-
Aldrich, St. Louis, MO; 1:1000) and/or Collagen III
(#ab7778, Abcam, Cambridge, UK; 1:200) diluted in block-
ing buffer, were then applied for 2 h at room temperature
in a humidified chamber, followed by 3 × 5 min PBS wash,
then one hour of Alexa Fluor 594-conjugated goat anti-
rabbit (for Col3) or goat anti-mouse (for Col1) IgG second-
ary antibodies (1:500 in 2 % goat serum, 0.25 % BSA;
Invitrogen, Carlsbad, CA). Optimal antibody dilutions and
incubation times were pre-determined empirically. Follow-
ing staining for col1 and/or col3, lung sections were
washed 3 × 5 min in PBS and mounted in ProLong Gold
Antifade reagent (without DAPI; Invitrogen, Carlsbad, CA),
then allowed to dry before imaging. Imaging and quantifi-
cation of these tissues labeled for col1 and col3 was then
performed as described in “Col1/Col3 ratio imaging” below.
Hematoxylin-eosin (H&E) staining was performed by
standard methods as previously described [19].
Two photon and SHG microscopy
FSHG/BSHG Imaging
Formalin fixed paraffin embedded human lung tissue
sections for healthy, UIP and COP were obtained and
prepared on slides as described above then imaged (un-
stained, unless otherwise described) for forward (FSHG)
and backward (BSHG) SHG signals as previously described
[19, 26, 27] and as excerpted in part herein, with modifica-
tions. We [26] and others [28] have demonstrated that
reliable FSHG/BSHG data is obtained from paraffin embed-
ded human biopsy tissues. Double-blinded samples wereimaged using a custom built multiphoton microscope, with
a Mai Tai titanium:sapphire laser (Newport/Spectra Physics,
Santa Clara, CA) providing two-photon (2P) excitation
(100 fs pulses at 80 MHz and 810 nm) which was circularly
polarized by passing the beam through a Berek compensa-
tor (Model 5540, New Focus, Irvine, CA) before the scan-
ner. Beam scanning and image acquisition were performed
with a custom-modified Fluoview FV300 confocal scanner
interfaced with a BX61WI upright microscope (Olympus,
Center Valley, PA), with an Olympus XLUMPLFL20xW
water immersion lens (20×, 0.95 N.A.) collecting the
epi-directed backscattered SHG (BSHG) and an Olympus
0.9 N.A. optical condenser simultaneously collecting the
forward-scattered SHG (FSHG) using HQ405/30 m-2P
emission filters (Chroma, Rockingham, VT) and HC125-02
photomultiplier tubes (PMTs) (Hamamatsu Corporation,
Hamamatsu, Japan) for both FSHG and BSHG. Excitation
light (810 nm) was separated from emission signals by a
short pass dichroic mirror (Chroma 670 DCSX) on the
backwards (BSHG) side, and a 565 nm long pass dichroic
mirror (565 DCSX, Chroma) on the forward (FSHG) side.
Thus FSHG and BSHG were simultaneously captured in two
distinct channels on every scan. The resulting two-channel
(FSHG and BSHG) images were 680 microns across. Laser
power was monitored and kept constant throughout each
experiment and across experimental repetitions, as were
PMT voltage, gain, and offset. Because the goal was to com-
pare relative differences in FSHG/BSHG between the experi-
mental conditions, and all experimental conditions to be
compared were imaged during each imaging session, fur-
ther calibration of the PMTs (e.g. to a reference standard)
was not required.
Using these methods, we obtained z-stacks (3 um steps
over the entire tissue thickness) for FSHG and BSHG in
two channels simultaneously, from 3-6 sections, ~5
random collagen-containing regions of interest (ROIs)
(images)/section, and 15–30 ROIs total per patient, for
N = 5, 5, and 10 Healthy, COP, and UIP patients respect-
ively. All data was plotted as N = number of patients per
group. For each channel (FSHG and BSHG), the image
stack was maximum intensity projected (which effect-
ively “autofocuses” each Z-stack into comparable single
images), then image analysis was performed with ImageJ
as previously described [19, 26, 27]. Briefly, background
was defined by the average pixel counts of an equivalent
laser-excited maximum intensity projected image stack
taken from an area of the slide with no tissue, and sub-
tracted from the raw FSHG or BSHG maximum intensity
projected image stacks. These background subtracted
FSHG and BSHG images were divided to create an FSHG/
BSHG ratio image. To calculate FSHG/BSHG, a common
threshold was applied to all FSHG/BSHG ratio images to
distinguish fibrillar collagen pixels from background
pixels, and subthreshold background (i.e. non collagen
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masking. This average FSHG/BSHG value from each image
was averaged across all images per patient, to yield a
single representative FSHG/BSHG value for each patient,
which were then expressed as mean FSHG/BSHG ± SEM
for the Healthy, COP, and UIP patient populations.Col1/Col3 ratio imaging
The same patient sets or subsets as described above for
FSHG/BSHG imaging were immunofluorescently (IF) la-
beled for Col1 and Col3 as described in “Histology and
Immunohistochemistry” above. Following this labeling
with anti-Col1 and anti-Col3 antibodies, two photon im-
aging was performed as described for FSHG/BSHG, except
now two-photon excited fluorescence (TPEF) for immu-
nofluorescently labeled Col1 or Col3 was captured in the
backwards (epidirected) channel only, with the IF signal
captured with a HQ635/30 m-2P emission filter (Chroma)
and HC125-01 Hamamatsu PMT. Z-stacks from each ROI
were obtained, intensity projected, and background sub-
tracted for all sections and ROIs per patient as described
for FSHG/BSHG above. Fluorescent intensities from the re-
sultant images were quantified with ImageJ and then
expressed as mean anti-Col1 or anti-Col3 IF pixel intensity
± SEM per patient, as described above and previously [19].
Col1:Col3 ratio was quantified in the same fashion, then
dividing the mean Col1/Col3 signals for each patient.Collagen/elastin ratio imaging
The same patient sets or subsets were imaged and quan-
tified for total FC content (i.e. total FSHG + BSHG signals)
and intrinsic autofluorescence (AF) from mature lung
elastin (captured at 515–555 nm), as follows. Imaging
was performed exactly as for FSHG/BSHG. Immediately
after each simultaneous FSHG and BSHG stacks was taken,
the backward channel filter was replaced with a 535/40
emission filter (Chroma) and a replicate stack taken, to
capture intrinsic autofluorescence (AF) from mature
lung elastin in exactly the same ROIs from which colla-
gen SHG was obtained. Elastin AF, FSHG, and BSHG im-
ages were processed as described above. This mean
Elastin AF signal per patient ± SEM was quantified and
expressed both by itself and relative to the total FC sig-
nal (i.e. total SHG signal, or FSHG + BSHG).Statistical analyses
All data are expressed as patient means +/- SEM. A one
way ANOVA with Dunnett’s post-hoc tests correcting for
multiple comparisons were used to establish statistical
significance using “R” (http://www.R-project.org) and
GraphPad Prism (http://www.graphpad.com) software.
Results were considered significant if p < 0.05.Results
Fibrillar collagen microstructure in the ECM is different in
UIP, but not COP, versus healthy lung
SHG in general is sensitive to changes in collagen micro-
structure including regularity or ordering of collagen fi-
brils within larger collagen fibers; fibril compaction; and
fibril diameter, tilt angle, or pitch angle [17–22, 29–34].
SHG is emitted both forwards and backwards (i.e. epi-
directed) from the SHG-generating scatterers in the focal
volume, and the FSHG/BSHG ratio in particular is primarily
sensitive to the spatial extent of SHG-generating scatterers
along the optical axis, i.e. the effective diameter or packing
arrangement/density/order versus disorder of collagen fi-
brils within the SHG focal volume [18–22, 26]. Therefore,
to determine if a relatively intractable lung fibrosis such as
UIP has a different underlying FC microstructure in the
ECM versus a treatable lung fibrosis such as COP, or versus
healthy lung, we used SHGM to interrogate the mean
FSHG/BSHG ratio in the ECM of UIP, COP, and healthy lung
tissues. Intriguingly, we found this FSHG/BSHG ratio was
significantly decreased UIP versus healthy lung, but un-
changed in COP versus healthy lung (Fig. 1). Figure 2 illus-
trates the results quantified in Fig. 1 with representative
FSHG, BSHG, and FSHG/BSHG images from each condition.
Although corresponding clinical data such as symptoms or
pulmonary function testing was not available, all patients
with UIP and COP had moderate to severe pathology on
the biopsy specimens. Importantly, the lack of significant
variability in the FSHG/BSHG ratio between patients in each
disease group and between healthy controls suggests
there is a disease specific phenotype. Additional stud-
ies will be necessary to determine whether there is a
difference in the FSHG/BSHG ratio seen in UIP on the
basis of disease severity.
Figure 3 shows representative H&E staining (2A-C)
matched to the same fields of view (FOVs) for FSHG (2D-
F) for healthy, COP, and UIP respectively, and illustrates
that the SHG signal (white pixels, 2D-F) quantified from
these lung tissues arises as expected chiefly from small
airways (yellow arrows) and parenchymal alveolar space
in healthy lung (2A/D), and from fibrotic collagen de-
position (blue arrows) in COP (2B/E) and UIP (2C/F).
Together these results show that FC microstructure is
altered in UIP but not in COP versus healthy lung.
Lung tissue with preserved alveolar architecture adjacent
to UIP fibroblastic foci or honeycomb areas has different
fibrillar collagen microstructure versus healthy lung
Next, we wondered whether lung tissue with preserved
alveolar architecture adjacent to UIP fibroblastic foci or
honeycomb areas also had different FC microstructure
versus healthy lung as measured by FSHG/BSHG, which
might suggest the possibility of underlying collagen struc-
















Fig. 1 Fibrillar collagen microstructure is different in UIP, but not
COP, versus healthy lung. SHG imaging was performed on healthy,
COP, and UIP formalin fixed paraffin embedded human lung tissue,
and the FSHG/BSHG ratio was calculated to assess relative differences
in FC microstructure. Plot represents mean FSHG/BSHG pixel intensity ±
SEM for each disease, calculated as described in Methods. Compared to
healthy lung tissue, FSHG/BSHG was significantly decreased only in UIP
(**p< .0018) but not COP. Plots were generated from a total of 15–30
sections and 75–150 distinct ROIs from N= 5 patients (Healthy and COP),
and 30–60 sections and 150–300 distinct ROIs from N= 10 patients (UIP).
All data was plotted as N = number of patients per group. Statistics
were performed by one way ANOVA with Dunnett’s post-hoc test
and correction for multiple comparisons against healthy control.
F/B SHG values are a ratio of mean pixel intensities in relative
arbitrary fluorescent units (AFU)
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rounding normal appearing lung tissue in UIP all had simi-
lar FSHG/BSHG ratios, which were all different versus the
FSHG/BSHG of healthy lung tissue (Fig. 4). These results pro-
vide an exciting, previously unreported “first glance” into
the biologic underpinnings of UIP as relates to FC micro-
structure, and suggest the possibility that pre-existing alter-
ations in FC microstructure even in “normal” lung tissue
may foreshadow or precipitate development of UIP.
Col1, Col3, and Col1/Col3 ratio differences in UIP versus
COP and healthy lung
Col1 and col3 are implicated in the pathology of UIP
and COP, and as fibrotic diseases, col1 and col3 levels in
UIP and COP are anticipated to be higher compared to
healthy lung. Moreover, previous reports have suggested
that col1 is the primary collagen deposited in UIP,
whereas col3 assumes this role in COP [1]. Importantly,
relative col1 and col3 expression levels can interact to
regulate aspects of collagen microstructure such as col-
lagen fibril or fiber diameter [23–25]. Conversely, by al-
tering availability of fibroblast (or other effector cell
type) binding sites on collagen fibrils, changes in colla-
gen’s subresolution fibril microstructure may regulate
relative collagen expression levels. Therefore, we wished
to determine how changes in FSHG/BSHG ratio (Fig. 1),indicative of altered collagen microstructure in lung
ECM, correspond with changes in col1/col3 deposition
in UIP, COP, and healthy lung.
We found higher col1 levels in both UIP and COP
compared to healthy lung, with UIP showing the highest
col1 levels versus COP and healthy (Fig. 5a). Both UIP
and COP had similarly elevated col3 levels versus
healthy lung (Fig. 5b). Overall, this resulted in relative
col1:col3 ratios that were significantly elevated in UIP
versus healthy controls, but not in COP versus healthy
controls (Fig. 5c). Fig. 5d-f illustrate higher Col3 levels
in COP (4E) and UIP (4 F) versus healthy (4D), as is
shown in 4B. Together, these results demonstrate the ex-
pected evidence of fibrosis in both UIP and COP com-
pared to healthy lung controls, and confirm previous
observations of higher relative col1:col3 deposition in
UIP, versus more abundant col3 over col1 deposition in
COP [1].
These Col1:Col3 ratio findings are also interesting in
the context of the FSHG/BSHG differences demonstrated
in Fig. 1, because altered Col1:Col3 ratios are reported
to regulate collagen fibril diameter and/or structure (i.e.
FC microstructure) [23–25], and accordingly UIP shows
a difference in both col1:col3 ratio (Fig. 5c) and FSHG/
BSHG (i.e. FC microstructure) (Fig. 1) versus healthy
lung, whereas COP shows neither a difference in col1:-
col3 ratio nor FSHG/BSHG versus healthy lung. Overall,
these results suggest a possible relationship between FC
microstructure differences and altered col1:col3 ratios in
intractable UIP fibrosis, but not in the more treatment
responsive COP fibrosis.
Elastin and elastin:collagen ratios differ in UIP and COP
versus healthy lung
In parallel with SHGM imaging, intrinsic tissue autoflu-
orescence representing principally mature lung elastin
can be captured simultaneously with SHG [35], to pro-
vide additional insights into how ECM structure and
organization may differ in UIP versus COP. Elastin is
another lung ECM component that interacts closely with
collagen to regulate lung function [36–39] and is fre-
quently dysregulated in fibrotic lung diseases [40, 41].
Elastin’s intrinsic autofluorescence captured by two-
photon excitation fluorescence (TPEF) microscopy arises
from the pyridoxine-based pyridolamine cross-links [35,
42] found only in mature elastin fibers [43], thus making
TPEF of elastin a useful indicator for the mature elastin
fiber content of lung tissue. Therefore, we captured this
signal for the same healthy, UIP, and COP specimens,
then quantified and expressed it both by itself and
relative to the total FC signal (i.e. total SHG signal, or
FSHG + BSHG), to see whether there were other under-
lying differences in ECM structure or organization that
we could identify and quantify by SHGM and two-
Fig. 2 Illustration of FSHG, BSHG, and FSHG/BSHG imaging as seen in Fig. 1. SHG imaging was performed on healthy, COP, and UIP formalin fixed
paraffin embedded human lung tissue, and FSHG, BSHG, and FSHG/BSHG ratio images obtained, as described for Fig. 1. Panels a–c, showing look-up-table
(LUT) “heatmaps” applied to the FSHG/BSHG ratio pixel values for representative FSHG/BSHG images, illustrate that Healthy lung tissues have the lowest
collagen content (as expected) but higher FSHG/BSHG ratios compared to COP and UIP which evidence fibrosis and lower average FSHG/BSHG ratios as
quantified in Fig. 1. Panels d–f and g–i respectively show the corresponding FSHG and BSHG images for each condition, with Healthy tissue again showing
the lowest collagen content and highest FSHG signal intensity relative to BSHG signal intensity (i.e. the highest FSHG/BSHG ratio), whereas COP has high fibrosis
and slightly higher BSHG relative to FSHG signals (intermediate FSHG/BSHG ratio), and UIP also has evident fibrosis and the least differential between the FSHG
and BSHG signal intensities (i.e. the lowest FSHG/BSHG ratio). Levels (screen stretch) are linear and set the same for images a–c and d–i
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this methodology, total mature elastin signal was similarly
decreased in both UIP and COP compared to healthy lung
tissue (Fig. 6a), and FC:mature elastin ratios (Fig. 6b) were
similarly increased in UIP and COP compared to healthy.
However, in neither of these parameters was UIP differentfrom COP. Panels 5C-D illustrate the lower FC:mature
elastin ratio seen in healthy versus UIP respectively.
These data demonstrate that compared to healthy lung,
both fibrotic lung diseases (UIP and COP) are characterized
by significant gross physiologic disruptions in ECM struc-
ture and organization that can be quantified with non-
Fig. 3 Healthy, COP, and UIP lung histopathology compared to FSHG. Representative hematoxylin and eosin (H&E) FOVs showing healthy a versus
fibrotic COP b and UIP c pathology were field-matched to the FSHG images d, e, f for the same FOVs, respectively. Note the eosin stained areas
of concentrated collagen deposition (light pink color, indicated by blue arrows in b and c) that match areas of high FC FSHG signal intensity
(white pixel regions, indicated by blue arrows in e and f) in COP and UIP respectively. In contrast, the FSHG (collagen) signal in healthy tissue d
arises primarily from alveolar parenchyma and muscular arteries (examples of muscular arteries are indicated by yellow arrows, in all images). Thus
SHGM detects and allows quantification of altered microstructure (e.g. Figs. 1, 3 and Fig. 5) from both intrinsic normal and pathologic collagen
content in lung tissue. Levels (screen stretch) are linear and set the same for all images d–f
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TPEF microscopy. Yet only the more intractable UIP
fibrosis shows evidence of disrupted FC microstruc-
ture as interrogated by FSHG/BSHG, thus highlighting
the compelling possibility that together these tech-
niques may help make clinical distinctions between in-
tractable and treatable lung fibroses.Discussion
Pulmonary fibrosis is characterized by accumulation of
ECM proteins in lung tissue. The mechanisms leading
to pathologic (or non pathologic) accumulation and
organization of matrix proteins remain poorly understood.
Although we have some insight into the composition,
structure and/or organization of the matrix, many proper-
ties of the matrix remain uninvestigated. Numerous matrix
proteins likely contribute to organ dysfunction in pulmon-
ary fibrosis, however, we are only beginning to understand
how homeostasis and organization of these proteins impact
cellular function.Collagen, produced and organized mainly by fibroblasts
and scar-forming myofibroblasts, is one of the most abun-
dantly studied matrix proteins. At least twenty-eight differ-
ent collagen subtypes have been described to date. All
collagen species contain three alpha peptide sequences
forming a triple helix. Collagen type is determined by the
type(s) of alpha peptides and post translational modifica-
tions, hydroxylation, and/or glycosylation. Further modifi-
cation of collagen structure occurs after release into the
extracellular space. Here, crosslinking and joining of the
helices occur to form collagen fibrils and larger collagen fi-
bers, and fibrosis (aberrant excess deposition of collagen)
may occur.
Due to their ability to provide information on the in-
trinsic content and structure of collagen and other en-
dogenous ECM proteins without exogenous labels or
tissue destroying procedures (see description of SHGM
and TPEF in Background and Results, respectively),
there has been increasing interest in using SHGM and
TPEF to provide insights into the matrix structure of


















Fig. 4 Lung tissue with preserved alveolar architecture adjacent to
UIP fibroblastic foci and honeycomb areas have different fibrillar
collagen microstructure versus healthy lung. SHG imaging of the
FSHG/BSHG ratio was performed on healthy (Hlthy) and UIP lung
tissue in areas with preserved alveolar architecture adjacent (UIPadj)
and compared to UIP fibroblastic foci (UIPff) and honeycomb
regions (UIPhc). Methodology was otherwise as described in Fig. 1.
The FSHG/BSHG ratio was significantly decreased in UIPadj (**p< .0036)
and UIPff (**p < .0054) and UIPhc (**p < .0007) versus healthy lung
tissue – whereas UIPadj, UIPff, and UIPhc were not significantly
different from each other – suggesting that even “normal appearing”
lung tissue in UIP patients has altered FC microstructure. Plots were
generated from a total of 15–30 sections and 75–150 distinct ROIs
from N = 5 patients (Healthy and UIPff); 18–36 sections and 90–180
distinct ROIs from N = 6 patients (UIPadj); and 30–60 sections and
150–300 distinct ROIs from N = 10 patients (UIPhc). All data was
plotted as N = number of patients per group. Statistics were performed
by one way ANOVA with Dunnett’s post-hoc test and correction for
multiple comparisons against healthy control. F/B SHG values are a
ratio of mean pixel intensities in relative AFU
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cancers, not discussed herein). One group reported that
combined TPEF and SHG identified “characteristic fea-
tures of fibroblastic foci in human Idiopathic Pulmonary
Fibrosis samples” [47], whereas another report used
FSHG and BSHG signals to differentiate Col1 from Col3 in
lung tissue from patients with chronic obstructive pul-
monary disease (COPD) [48]. Also in COPD, Tjin et al.
found the FSHG/BSHG ratio was different in COPD ver-
sus non-diseased lung tissue [28]. However, reports
demonstrating a diagnostic capability of quantifiable
SHGM and TPEF parameters to discriminate between
different clinical lung fibroses, or perhaps more im-
portantly to provide insights into the underlying eti-
ology or structure-function origins of lung disease, are
still scarce.
In this report, we extend these works by using SHGM
and TPEF imaging to identify key differences in the
ECM of UIP compared to COP and healthy control lung
tissue. UIP and COP were chosen because they are bothcharacterized by increases in matrix proteins, particu-
larly FCs, yet they have contrasting natural histories, re-
sponses to corticosteroids, and prognoses. The reasons
why UIP is progressive and difficult to treat are not
clear. One possible explanation is that there may be a
fundamental difference in collagen’s content, structure,
and/or organization in the UIP ECM that renders colla-
gen more structurally more resistant to degradation in
UIP versus COP. We tested this hypothesis using
SHGM, a microscopy approach that is sensitive to the
intrinsic FC organization and microstructure within the
matrix, to confirm whether FC in UIP has different
microstructural properties versus COP or healthy lung.
Using this approach, we have demonstrated that FC
microstructure in the ECM of UIP is significantly differ-
ent from FC microstructure in either COP or healthy
control lung tissue, as evidenced by the FSHG/BSHG ratio.
Changes in this FSHG/BSHG ratio suggest that there is a
significant difference in the density, structure, and/or
organization of FC in UIP compared to COP and healthy
lung tissue, particularly with regard to the effective
diameter or packing arrangement/density of collagen fi-
brils in the ECM [18–22, 26]. These results are compel-
ling because while previous studies (discussed above)
have elegantly demonstrated the utility of SHGM for in-
vestigating lung fibroses, or have shown expression
changes in several collagen subtypes in fibrotic lung dis-
eases, to our knowledge this is the first report of abnor-
malities in ECM and FC microstructure in UIP as being
quantifiable and differentiable from other lung fibroses
(and from healthy) by SHGM, specifically FSHG/BSHG.
Still more compelling is the fact that only the intractable
fibrosis (UIP) demonstrated significant differences in FC
microstructure versus healthy lung, whereas the treat-
able fibrosis (COP) did not, thus providing compelling
and to our knowledge seminal evidence that alterations
in collagen’s fundamental underlying structure may
contribute to whether or not pulmonary fibroses are
treatment responsive. These results provide previously
unavailable insights into the biological underpinnings of
treatment-resistant pulmonary fibrosis, and also high-
light the potential of SHGM as a novel clinical diagnos-
tic and investigational tool for distinguishing between
intractable and treatable lung fibroses.
We also found that lung tissue with preserved alveolar
architecture adjacent to UIP fibroblastic lesions and
honeycomb areas all have different FC microstructure
(i.e. FSHG/BSHG) versus healthy lung. Moreover, there
was no difference in FSHG/BSHG between UIP fibroblastic
foci, honeycomb areas, and adjacent areas with pre-
served alveolar architecture (Fig. 4). Together these re-
sults suggest the possibility that pre-existing alterations
in FC structure even in “normal” lung tissue may fore-
shadow or precipitate (or at minimum, associate with)
Fig. 5 Increased Col1 and Col3 deposition, and Col1:Col3 ratio differences, in UIP or COP versus healthy lung. a Compared to healthy, Col1
deposition was significantly increased in UIP (**p < .0033) and trended toward an increase in COP (p = .13). b Col3 deposition was about equally
increased in both COP (**p < .009) and UIP (**p < .004) versus healthy. Overall, this led to c The Col1:Col3 ratio being effectively equivalent in
COP versus healthy, but significantly increased in UIP versus healthy (*p < .015). Plots were generated from≥ 9-18 sections and≥ 45–90 distinct
ROIs from N≥ 3 patients per condition. All data was plotted as N = number of patients per group. Statistics were performed by one way ANOVA
with Dunnett’s post-hoc test and correction for multiple comparisons against healthy control. Values for Collagen I and III represent mean
immunofluorescence pixel intensities in relative AFU (Panels a, b), or a ratio thereof (Panel c). In panels d–f, for illustrative purposes, the originally
grayscale Col3 immunofluorescence is shown with “Red” LUT applied in ImageJ for Healthy, COP, and UIP respectively, with levels (screen stretch)
linear and set the same for all images. Note the round Masson’s bodies characteristic of COP (in e), whereas f respresents an area of widespread
late-stage fibrosis in UIP
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structural deficits – perhaps present in pre-UIP tissue
well before the onset of UIP – might be a biomarker that
predicts or predisposes development of future UIP.
As expected, both col1 and col3 were elevated in UIP
and COP versus healthy lung, with col1 deposition being
predominant to col3 in UIP, and vice-versa in COP, as
has been previously reported [1]. These results are sig-
nificant in the context of our other results reported
herein because it is known that changes in FC ratios,
particularly col1:col3 ratios, plays a significant role in
regulating collagen fibril diameter [23–25] (one compo-
nent of collagen microstructure). Similarly, by regulating
the availability of fibroblast (or other effector cell type)
binding sites on collagen fibrils, changes in collagen’s
subresolution fibril microstructure could in turn control
relative levels of FC expression. In other words, different
col1:col3 ratios may in turn drive or be driven by altered
collagen microstructure in UIP. Together with the earl-
ier data, these results demonstrate that the ECM of UIP
not only contains more collagen (particularly more col1)
than the ECM of COP and/or healthy lung tissue, but
also that there are significant differences in the subresolu-
tion microstructure of these collagen fibrils (i.e. fibril
diameter, density, and/or organization, as interrogated by
FSHG/BSHG) in UIP versus COP and healthy, independentof the absolute amount of collagen deposition in each
disease.
Finally, we demonstrated that mature elastin content
in both UIP and COP is reduced compared to healthy
controls (Fig. 6). Elastin’s intrinsic autofluorescence orig-
inates from pyridoxine-based pyridolamine cross-links
[35, 42] found primarily in mature elastin fibers [43],
therefore TPEF of endogenous lung elastin preferentially
identifies mature elastin fibers in lung tissue. These re-
sults are consistent with the concept that breakdown of
mature elastin fibers in the lung, and their “replacement”
with often excess deposition of immature elastin fibers
and elastin precursors, is believed to contribute to re-
duced lung function in a variety of pulmonary diseases
[49]. In other words, increased elastosis (i.e. breakdown
of mature elastin fibers), as has been demonstrated for
both UIP and COP [50], most likely leads to a compen-
satory increase in elastin production in an (ultimately
unsuccessful) effort to restore the mature elastin fibers
which have been lost.
Hence our results here together with these previous
studies all support the concept of increased elastin turn-
over (i.e. synthesis and “deposition” of “immature” elas-
tin components) consequent to breakdown and loss of
mature elastin fibers in UIP and COP, with resultant def-
icits in pulmonary function. Indeed Enomoto et al. show
Fig. 6 Elastin content and Collagen:Elastin ratio differ in UIP and COP versus healthy lung. a Mature elastin fiber content was similarly decreased
in both COP (*p < .007) and UIP (*p < .004) versus healthy lung tissue, and b The total fibrillar collagen/mature elastin ratio was similarly increased
in both COP (**p < .004) and UIP (**p < .0008) compared to healthy. Plots represent mean pixel intensity ± SEM for these elastin autofluorescence
(Panel a) and (FSHG + BSHG/ Elastin autofluorescence) (Panel b) signals captured as described in Methods, in relative AFU. Plots were generated
from a total of 12–24 sections and 60–120 distinct ROIs from N = 4 patients (Healthy and UIP), and 9–18 sections and 45–90 distinct ROIs from
N = 3 patients (COP). All data was plotted as N = number of patients per group. Statistics were performed by one way ANOVA with Dunnett’s
post-hoc test and correction for multiple comparisons against healthy control. Representative merged images c and d illustrate this lower total
FC SHG (blue):mature elastin (green) ratio as seen in c healthy compared to d UIP. (Compare total amount and intensity of the blue summed
FSHG + BSHG collagen SHG signal, relative to the green mature elastin signal, in the healthy c versus UIP d panels respectively). Panel d respresents
an area of widespread late-stage fibrosis in UIP. For illustrative purposes, the originally grayscale SHG and elastin fluorescence signals are shown
with “Blue” and “Green” LUTs applied in ImageJ respectively, with levels (screen stretch) linear and set the same for all channels in all images
Kottmann et al. Respiratory Research  (2015) 16:61 Page 10 of 13a significant increase in very fragmented appearing elas-
tin (i.e. likely to be fragmented mature elastin fibers
and/or deposition of immature elastin precursors; see
Fig. 1 in [51]) associated with a decline in lung function
in IPF [51]. Others have also reported apparently in-
creased elastin production, for example increased elastin
gene expression and protein expression [52], as well as
increased enzymatic breakdown of mature elastin in
COPD and IPF [50], in these and other [53] pulmonary
fibroses. Finally Eurlings et al. recently reported in-
creased collagen and decreased elastin in aveolar and
small airway walls of chronic obstructive pulmonary dis-
ease (COPD) [54], another disease with fibrotic path-
ology, similar to what we demonstrate herein for COP
and UIP (Fig. 3 and Fig. 5).Taken together with our findings on different FC
microstructure in UIP but not COP versus healthy lung,
these observations on elastin content are especially
compelling because they demonstrate that compared
to healthy lung, both fibroses (UIP and COP) have
significant identifying physiologic disruptions in ECM
structure and organization that are quantifiable with
non-invasive and non-tissue destructive combined SHG
and TPEF microscopy. Yet only the more intractable
UIP fibrosis has disrupted FC microstructure identifiable
by FSHG/BSHG, and thus together these techniques may
represent novel clinical diagnostic tools for distinguish-
ing between intractable and treatable lung fibroses. The
continual pre-clinical advancement of SHG and TPEF
endoscopic technology makes the prospect of such a
Kottmann et al. Respiratory Research  (2015) 16:61 Page 11 of 13diagnostic tool for distinguishing between intractable and
treatable lung fibroses all the more compelling [17, 55].
While both UIP and COP are fibrotic diseases, UIP is
a fatal disease affecting the alveolar walls and subpleural
areas, while COP is a treatable disease affecting the al-
veolar spaces and bronchiolar lumen. Thus while both
have fibrosis, their topography and natural history are
distinct, and therefore any inter-disease comparative
study of this nature cannot completely exclude the pos-
sibility that some measured differences might be attrib-
utable at least in part in part to temporal or anatomical/
topographical differences in the lung tissues examined
between the patient groups. Moreover, incorporating
additional corresponding clinical data such as symptoms
or pulmonary function testing (unavailable for these
current patient sets) will allow us to strengthen our
findings and interpretations in future studies. None-
theless the possibility that non-invasive and non-tissue
destructive combined SHG and TPEF microscopy,
utilized either ex vivo or perhaps ultimately in vivo,
may be able to distinguish and/or predict onset or out-
come of tractable versus fatal lung fibroses remains
compelling.
In summary, using SHG and TPEF microscopy, herein
we identify several previously unreported key differences
between UIP, COP and healthy lung tissue. The collagen
microstructure differences we observed in UIP ECM
provide novel insights as to why this pathology may be
resistant to many therapies. For example, an ECM and/
or collagen fibrils that are more densely packed, more
ordered or disordered, and/or more cross-linked may be
more resistant to homeostatic turnover and exhibit dif-
ferences in matrix stiffness that are key to modifying cel-
lular activity of resident cells and activation of pro-
fibrogenic cytokines such as transforming growth factor
beta (TGF- β. Identifying all the microstructural changes
present in UIP and/or the mechanisms that regulate
them will be a critical part of our future research. These
ongoing studies will seek to determine more specifically
exactly what features of collagen’s microstructure (e.g. fi-
bril diameter, fibril density, and/or hetero- or homo-
typic fibril composition or organization) are different in
UIP versus COP and healthy lung, and identify molecu-
lar targets that may effect these changes in collagen’s
underlying microstructure. Although further studies are
required to ascertain whether or not the altered FC
microstructure as we demonstrate here is an underlying
cause of (rather than just associated with) differences in
natural history, treatment responsiveness, and/or prog-
nosis between UIP and COP, at minimum these results
introduce the intriguing possibility of using SHG mi-
croscopy as a novel clinical biomarker that may help
predict treatment responsiveness of idiopathic fibrotic
lung disease.Conclusions
To date it is unknown why some lung fibroses respond
well to therapies, yet others remain relatively intractable.
Herein, we report differences in collagen’s subresolution
structure or organization (i.e. “microstructure”) and
airway matrix structure in usual interstitial pneumonia
versus cryptogenic organizing pneumonia and healthy
lung, as identified by quantifiable nonlinear SHG and
TPEF microscopy parameters. These findings may offer
key insights into the biologic underpinnings of refractory
versus treatable pulmonary fibroses, and highlight the
potential of second harmonic generation microscopy as
a novel diagnostic tool for distinguishing between these
clinical scenarios.
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